Search Within

Sham Mailankody

Formats
  1. Meeting Abstract (169)
  2. Journal Article (96)
  3. Research Letter (12)
  4. Review (10)
  5. Correspondence (4)
  6. Editorial (2)
  7. Guidelines (1)
Groups
  1. Center for Hematologic Malignancies (294)
  2. Department of Medicine (294)
  3. Hematologic Malignancies, Division of (294)
  4. Myeloma (294)
  5. Survivorship Research (213)
  6. Hematologic Malignancies Research (209)

More Groups

People
  1. Neha Korde (188)
  2. Alexander Lesokhin (167)
  3. Hani Hassoun (160)
  4. Sergio Giralt (158)
  5. Malin Hultcrantz (155)
  6. Heather Landau (144)

More People

Years
  1. 2025 (10)
  2. 2024 (46)
  3. 2023 (49)
  4. 2022 (44)
  5. 2021 (22)
  6. 2020 (22)

More Years

Publications
  1. Blood (96)
  2. Clinical Lymphoma, Myeloma and Leukemia (46)
  3. Journal of Clinical Oncology (23)
  4. JAMA Oncology (12)
  5. Blood Cancer Journal (11)
  6. Leukemia and Lymphoma (10)

More Publications

Publishers
  1. American Society of Hematology (106)
  2. Elsevier Inc. (70)
  3. Nature Publishing Group (25)
  4. American Society of Clinical Oncology (24)
  5. American Medical Association (18)
  6. Taylor & Francis Group (10)

More Publishers

Results (294)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Development and evaluation of a human single chain variable fragment (scFv) derived BCMA targeted CAR T Cell vector leads to a high objective response rate in patients with advanced MM
    Meeting Abstract

    Smith, E. L.; Mailankody, S.; Ghosh, A.; Masakayan, R.; Staehr, M.; Purdon, T. J.; Halton, E.; Diamonte, C.; Anant, P.; Bernal, Y.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • MRD response-driven phase I/II study for newly diagnosed multiple myeloma patients using higher doses of twice-weekly carfilzomib (45 and 56 mg/m2) in combination with lenalidomide and dexamethasone
    Meeting Abstract

    Korde, N.; Mailankody, S.; Smith, E. L.; Lendvai, N.; Hassoun, H.; Lesokhin, A.; Hultcrantz, M.; Chung, D. J.; Shah, G. L.; Koehne, G.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Clinically meaningful benefit: Real world use compared against the American and European guidelines
    Journal Article

    Dreicer, J. J.; Mailankody, S.; Fahkrejahani, F.; Prasad, V.
    Blood Cancer Journal (2017)

    Fulltext@MSK | Save
  • Obesity and risk of monoclonal gammopathy of undetermined significance and progression to multiple myeloma: A population-based study
    Journal Article

    Thordardottir, M.; Lindqvist, E. K.; Lund, S. H.; Costello, R.; Burton, D.; Korde, N.; Mailankody, S.; Eiriksdottir, G.; Launer, L. J.; Gudnason, V.; more...
    Blood Advances (2017)

    Fulltext@MSK | Save
  • Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12 372 individuals 10-49 years old: A population-based study from the National Health and Nutrition Examination Survey
    Journal Article

    Landgren, O.; Graubard, B. I.; Kumar, S.; Kyle, R. A.; Katzmann, J. A.; Murata, K.; Costello, R.; Dispenzieri, A.; Caporaso, N.; Mailankody, S.; more...
    Blood Cancer Journal (2017)

    Fulltext@MSK | Save
  • A further strategy to combat the high price of anticancer drugs
    Journal Article

    Prasad, V.; De Jesús, K.; Mailankody, S.
    Nature Reviews Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Research and development spending to bring a single cancer drug to market and revenues after approval
    Journal Article

    Prasad, V.; Mailankody, S.
    JAMA Internal Medicine (2017)

    Fulltext@MSK | Save
  • Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma
    Journal Article

    Mailankody, S.; Kazandjian, D.; Korde, N.; Roschewski, M.; Manasanch, E.; Bhutani, M.; Tageja, N.; Kwok, M.; Zhang, Y.; Zingone, A.; more...
    Blood Advances (2017)

    Fulltext@MSK | Save
  • Galinpepimut-S, a WT1-targeting immuno-oncology treatment, induces specific, robust and durable immune responses (IRs) in patients (Pts) with high-risk (HR) multiple myeloma (MM)
    Meeting Abstract

    Koehne, G.; Devlin, S.; Korde, N.; Mailankody, S.; Heather, L.; Hassoun, H.; Lesokhin, A.; Lendvai, N.; Chung, D.; Sarlis, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2017)

    Fulltext@MSK | Save
  • Immunophenotypic evidence for reactive polyclonal marrow plasmacytosis in multiple myeloma patients receiving lenalidomide maintenance
    Journal Article

    Hassoun, H.; Roshal, M.; Sabari, J.; Nguyen, J.; Gao, Q.; Devlin, S. M.; Landau, H.; Lendvai, N.; Chung, D. J.; Lesokhin, A. M.; more...
    Leukemia and Lymphoma (2017)

    Fulltext@MSK | Save